{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T06:58:45Z","timestamp":1791874725797,"version":"4.3.4"},"reference-count":155,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T00:00:00Z","timestamp":1651104000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosntds.org"],"crossmark-restriction":false},"short-container-title":["PLoS Negl Trop Dis"],"abstract":"<jats:p>Flaviviruses have caused large epidemics and ongoing outbreaks for centuries. They are now distributed in every continent infecting up to millions of people annually and may emerge to cause future epidemics. Some of the viruses from this group cause severe illnesses ranging from hemorrhagic to neurological manifestations. Despite decades of research, there are currently no approved antiviral drugs against flaviviruses, urging for new strategies and antiviral targets. In recent years, integrated omics data-based drug repurposing paired with novel drug validation methodologies and appropriate animal models has substantially aided in the discovery of new antiviral medicines. Here, we aim to review the latest progress in the development of both new and repurposed (i) direct-acting antivirals; (ii) host-targeting antivirals; and (iii) multitarget antivirals against flaviviruses, which have been evaluated both in vitro and in vivo, with an emphasis on their targets and mechanisms. The search yielded 37 compounds that have been evaluated for their efficacy against flaviviruses in animal models; 20 of them are repurposed drugs, and the majority of them exhibit broad-spectrum antiviral activity. The review also highlighted the major limitations and challenges faced in the current in vitro and in vivo evaluations that hamper the development of successful antiviral drugs for flaviviruses. We provided an analysis of what can be learned from some of the approved antiviral drugs as well as drugs that failed clinical trials. Potent in vitro and in vivo antiviral efficacy alone does not warrant successful antiviral drugs; current gaps in studies need to be addressed to improve efficacy and safety in clinical trials.<\/jats:p>","DOI":"10.1371\/journal.pntd.0010291","type":"journal-article","created":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T17:25:42Z","timestamp":1651166742000},"page":"e0010291","update-policy":"https:\/\/doi.org\/10.1371\/journal.pntd.corrections_policy","source":"Crossref","is-referenced-by-count":25,"title":["Finding a chink in the armor: Update, limitations, and challenges toward successful antivirals against flaviviruses"],"prefix":"10.1371","volume":"16","author":[{"given":"Thamil Vaani","family":"Komarasamy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4328-3376","authenticated-orcid":true,"given":"Nur Amelia Azreen","family":"Adnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9583-307X","authenticated-orcid":true,"given":"Vinod RMT","family":"Balasubramaniam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,4,28]]},"reference":[{"issue":"5","key":"pntd.0010291.ref001","doi-asserted-by":"crossref","DOI":"10.3390\/v9050097","article-title":"Historical Perspectives on Flavivirus Research.","volume":"9","author":"MR Holbrook","year":"2017","journal-title":"Viruses"},{"issue":"1","key":"pntd.0010291.ref002","doi-asserted-by":"crossref","DOI":"10.1128\/MMBR.00055-16","article-title":"The Antigenic Structure of Zika Virus and Its Relation to Other Flaviviruses: Implications for Infection and Immunoprophylaxis","volume":"81","author":"FX Heinz","year":"2017","journal-title":"Microbiol Mol Biol Rev"},{"key":"pntd.0010291.ref003","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.3389\/fimmu.2018.02180","article-title":"Flavivirus Receptors: Diversity, Identity, and Cell Entry","volume":"9","author":"M Laureti","year":"2018","journal-title":"Front Immunol"},{"key":"pntd.0010291.ref004","unstructured":"WHO. An R&D Blueprint for Action to Prevent Epidemics. 2016"},{"key":"pntd.0010291.ref005","author":"WHO","year":"2018","journal-title":"Prioritizing diseases for research and development in emergency contexts"},{"issue":"1","key":"pntd.0010291.ref006","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13073-018-0561-2","article-title":"Developing Zika vaccines: the lessons for disease X","volume":"10","author":"ADT Barrett","year":"2018","journal-title":"Genome Med"},{"issue":"5","key":"pntd.0010291.ref007","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1016\/S1473-3099(20)30123-7","article-title":"Disease X: accelerating the development of medical countermeasures for the next pandemic","volume":"20","author":"S Simpson","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"pntd.0010291.ref008","doi-asserted-by":"crossref","first-page":"e0007213","DOI":"10.1371\/journal.pntd.0007213","article-title":"Global expansion and redistribution of Aedes-borne virus transmission risk with climate change.","volume":"13","author":"SJ Ryan","year":"2019","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0010291.ref009","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1186\/1471-2458-14-781","article-title":"Climate change and the emergence of vector-borne diseases in Europe: case study of dengue fever.","volume":"14","author":"M Bouzid","year":"2014","journal-title":"BMC Public Health"},{"issue":"1","key":"pntd.0010291.ref010","doi-asserted-by":"crossref","first-page":"22989","DOI":"10.1038\/s41598-021-02061-0","article-title":"Urbanization favors the proliferation of Aedes aegypti and Culex quinquefasciatus in urban areas of Miami-Dade County, Florida.","volume":"11","author":"ABB Wilke","year":"2021","journal-title":"Sci Rep"},{"issue":"4 Suppl","key":"pntd.0010291.ref011","doi-asserted-by":"crossref","first-page":"3","DOI":"10.2149\/tmh.2011-S05","article-title":"Dengue, Urbanization and Globalization: The Unholy Trinity of the 21(st) Century.","volume":"39","author":"DJ Gubler","year":"2011","journal-title":"Trop Med Health"},{"issue":"8","key":"pntd.0010291.ref012","doi-asserted-by":"crossref","first-page":"e0005694","DOI":"10.1371\/journal.pntd.0005694","article-title":"Increasing airline travel may facilitate co-circulation of multiple dengue virus serotypes in Asia.","volume":"11","author":"H Tian","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"issue":"6","key":"pntd.0010291.ref013","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.mcna.2008.07.002","article-title":"Geographic expansion of dengue: the impact of international travel.","volume":"92","author":"A Wilder-Smith","year":"2008","journal-title":"Med Clin North Am"},{"key":"pntd.0010291.ref014","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s41182-020-00200-3","article-title":"The burden of Japanese encephalitis, the catch-up vaccination campaign, and health service providers\u2019 perceptions in Myanmar: 2012\u20132017","volume":"48","author":"AYN Win","year":"2020","journal-title":"Trop Med Health"},{"key":"pntd.0010291.ref015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40794-020-0101-0","article-title":"Yellow fever control: current epidemiology and vaccination strategies.","volume":"6","author":"LH Chen","year":"2020","journal-title":"Trop Dis Travel Med Vaccines"},{"issue":"10","key":"pntd.0010291.ref016","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1080\/21645515.2019.1658503","article-title":"A review of Dengvaxia(R): development to deployment.","volume":"15","author":"SJ Thomas","year":"2019","journal-title":"Hum Vaccin Immunother"},{"issue":"13","key":"pntd.0010291.ref017","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJMoa1506223","article-title":"Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease","volume":"373","author":"SR Hadinegoro","year":"2015","journal-title":"N Engl J Med"},{"issue":"3","key":"pntd.0010291.ref018","first-page":"351","article-title":"Dissecting Antibodies Induced by a Chimeric Yellow Fever-Dengue, Live-Attenuated, Tetravalent Dengue Vaccine (CYD-TDV) in Naive and Dengue-Exposed Individuals.","volume":"215","author":"S Henein","year":"2017","journal-title":"J Infect Dis"},{"key":"pntd.0010291.ref019","doi-asserted-by":"crossref","first-page":"572681","DOI":"10.3389\/fcimb.2020.572681","article-title":"Antibody-Dependent Enhancement: A Challenge for Developing a Safe Dengue Vaccine.","volume":"10","author":"R Shukla","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"key":"pntd.0010291.ref020","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.antiviral.2019.03.004","article-title":"Broad spectrum anti-flavivirus pyridobenzothiazolones leading to less infective virions","volume":"167","author":"R Cannalire","year":"2019","journal-title":"Antiviral Res"},{"issue":"3","key":"pntd.0010291.ref021","article-title":"Antiviral Activity of Benzavir-2 against Emerging Flaviviruses.","volume":"12","author":"YD Gwon","year":"2020","journal-title":"Viruses"},{"issue":"1","key":"pntd.0010291.ref022","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41598-020-58468-8","article-title":"Evaluation of the antiviral activity of orlistat (tetrahydrolipstatin) against dengue virus, Japanese encephalitis virus, Zika virus and chikungunya virus.","volume":"10","author":"A Hitakarun","year":"2020","journal-title":"Sci Rep."},{"key":"pntd.0010291.ref023","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jhealeco.2016.01.012","article-title":"Innovation in the pharmaceutical industry: New estimates of R&D costs.","volume":"47","author":"JA DiMasi","year":"2016","journal-title":"J Health Econ."},{"issue":"3","key":"pntd.0010291.ref024","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jacbts.2016.03.002","article-title":"Drugs, Devices, and the FDA: Part 1: An Overview of Approval Processes for Drugs.","volume":"1","author":"GA Van Norman","year":"2016","journal-title":"JACC Basic Transl Sci."},{"issue":"9324","key":"pntd.0010291.ref025","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1016\/S0140-6736(02)09096-7","article-title":"Drug development for neglected diseases: a deficient market and a public-health policy failure","volume":"359","author":"P Trouiller","year":"2002","journal-title":"Lancet"},{"issue":"10","key":"pntd.0010291.ref026","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.tim.2018.04.004","article-title":"Drug Repurposing for Viral Infectious Diseases: How Far Are We?","volume":"26","author":"B Mercorelli","year":"2018","journal-title":"Trends Microbiol"},{"issue":"6493","key":"pntd.0010291.ref027","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1126\/science.abb9332","article-title":"Rapid repurposing of drugs for COVID-19","volume":"368","author":"RK Guy","year":"2020","journal-title":"Science"},{"key":"pntd.0010291.ref028","article-title":"A SARS-CoV-2 protein interaction map reveals targets for drug repurposing","author":"DE Gordon","year":"2020","journal-title":"Nature"},{"key":"pntd.0010291.ref029","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41421-020-0153-3","article-title":"Network-based drug repurposing for novel coronavirus 2019-nCoV\/SARS-CoV-2","volume":"6","author":"Y Zhou","year":"2020","journal-title":"Cell Discov"},{"issue":"6","key":"pntd.0010291.ref030","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.tips.2020.03.006","article-title":"Ongoing Clinical Trials for the Management of the COVID-19 Pandemic","volume":"41","author":"MP Lythgoe","year":"2020","journal-title":"Trends Pharmacol Sci"},{"issue":"2","key":"pntd.0010291.ref031","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.chom.2016.07.004","article-title":"A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection","volume":"20","author":"NJ Barrows","year":"2016","journal-title":"Cell Host Microbe"},{"issue":"8","key":"pntd.0010291.ref032","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1038\/cr.2017.88","article-title":"Existing drugs as broad-spectrum and potent inhibitors for Zika virus by targeting NS2B-NS3 interaction","volume":"27","author":"Z Li","year":"2017","journal-title":"Cell Res"},{"issue":"10","key":"pntd.0010291.ref033","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1038\/nm.4184","article-title":"Identification of small-molecule inhibitors of Zika virus infection and induced neural cell death via a drug repurposing screen","volume":"22","author":"M Xu","year":"2016","journal-title":"Nat Med"},{"issue":"7","key":"pntd.0010291.ref034","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/j.cell.2018.11.028","article-title":"Comparative Flavivirus-Host Protein Interaction Mapping Reveals Mechanisms of Dengue and Zika Virus Pathogenesis","volume":"175","author":"PS Shah","year":"2018","journal-title":"Cell"},{"issue":"5","key":"pntd.0010291.ref035","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1016\/j.celrep.2018.01.038","article-title":"A Global Interactome Map of the Dengue Virus NS1 Identifies Virus Restriction and Dependency Host Factors","volume":"22","author":"ML Hafirassou","year":"2018","journal-title":"Cell Rep"},{"issue":"1","key":"pntd.0010291.ref036","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40169-017-0181-2","article-title":"A perspective on multi-target drug discovery and design for complex diseases.","volume":"7","author":"RR Ramsay","year":"2018","journal-title":"Clin Transl Med"},{"key":"pntd.0010291.ref037","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ejmech.2018.03.007","article-title":"Polypharmacology in HIV inhibition: can a drug with simultaneous action against two relevant targets be an alternative to combination therapy?","volume":"150","author":"S de Castro","year":"2018","journal-title":"Eur J Med Chem"},{"issue":"16","key":"pntd.0010291.ref038","doi-asserted-by":"crossref","first-page":"4246","DOI":"10.1073\/pnas.1720032115","article-title":"Flavivirus internalization is regulated by a size-dependent endocytic pathway","volume":"115","author":"BA Hackett","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"pntd.0010291.ref039","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nrmicro.2017.170","article-title":"Rewiring cellular networks by members of the Flaviviridae family","volume":"16","author":"CJ Neufeldt","year":"2018","journal-title":"Nat Rev Microbiol"},{"issue":"10","key":"pntd.0010291.ref040","doi-asserted-by":"crossref","DOI":"10.3390\/v11100929","article-title":"Flavivirus RNA-Dependent RNA Polymerase Interacts with Genome UTRs and Viral Proteins to Facilitate Flavivirus RNA Replication.","volume":"11","author":"Y Duan","year":"2019","journal-title":"Viruses"},{"issue":"1","key":"pntd.0010291.ref041","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens9010042","article-title":"Understanding Flavivirus Capsid Protein Functions: The Tip of the Iceberg.","volume":"9","author":"S Sotcheff","year":"2020","journal-title":"Pathogens."},{"key":"pntd.0010291.ref042","doi-asserted-by":"crossref","first-page":"15672","DOI":"10.1038\/ncomms15672","article-title":"A peptide-based viral inactivator inhibits Zika virus infection in pregnant mice and fetuses.","volume":"8","author":"Y Yu","year":"2017","journal-title":"Nat Commun."},{"key":"pntd.0010291.ref043","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.antiviral.2017.02.009","article-title":"Antiviral activity of peptide inhibitors derived from the protein E stem against Japanese encephalitis and Zika viruses","volume":"141","author":"L Chen","year":"2017","journal-title":"Antiviral Res"},{"issue":"4","key":"pntd.0010291.ref044","doi-asserted-by":"crossref","first-page":"e1000851","DOI":"10.1371\/journal.ppat.1000851","article-title":"Peptide inhibitors of dengue-virus entry target a late-stage fusion intermediate.","volume":"6","author":"AG Schmidt","year":"2010","journal-title":"PLoS Pathog."},{"issue":"3","key":"pntd.0010291.ref045","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1021\/acsinfecdis.8b00322","article-title":"Small Molecules Targeting the Flavivirus E Protein with Broad-Spectrum Activity and Antiviral Efficacy in Vivo.","volume":"5","author":"PC Li","year":"2019","journal-title":"ACS Infect Dis"},{"issue":"8","key":"pntd.0010291.ref046","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.chembiol.2018.05.011","article-title":"Inhibition of Flaviviruses by Targeting a Conserved Pocket on the Viral Envelope Protein.","volume":"25","author":"M de Wispelaere","year":"2018","journal-title":"Cell Chem Biol"},{"issue":"3","key":"pntd.0010291.ref047","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.cell.2015.06.057","article-title":"Structure-Guided Design of an Anti-dengue Antibody Directed to a Non-immunodominant Epitope","volume":"162","author":"LN Robinson","year":"2015","journal-title":"Cell"},{"issue":"6243","key":"pntd.0010291.ref048","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1126\/science.aaa8651","article-title":"DENGUE VIRUS. Cryo-EM structure of an antibody that neutralizes dengue virus type 2 by locking E protein dimers","volume":"349","author":"G Fibriansah","year":"2015","journal-title":"Science"},{"key":"pntd.0010291.ref049","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.antiviral.2017.04.015","article-title":"Characterization of the Zika virus two-component NS2B-NS3 protease and structure-assisted identification of allosteric small-molecule antagonists","volume":"143","author":"SA Shiryaev","year":"2017","journal-title":"Antiviral Res"},{"issue":"1","key":"pntd.0010291.ref050","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1089\/adt.2010.0309","article-title":"Virtual ligand screening of the National Cancer Institute (NCI) compound library leads to the allosteric inhibitory scaffolds of the West Nile Virus NS3 proteinase.","volume":"9","author":"SA Shiryaev","year":"2011","journal-title":"Assay Drug Dev Technol."},{"key":"pntd.0010291.ref051","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.antiviral.2017.07.007","article-title":"Structure-based discovery of clinically approved drugs as Zika virus NS2B-NS3 protease inhibitors that potently inhibit Zika virus infection in vitro and in vivo","volume":"145","author":"S Yuan","year":"2017","journal-title":"Antiviral Res"},{"key":"pntd.0010291.ref052","doi-asserted-by":"crossref","first-page":"104668","DOI":"10.1016\/j.antiviral.2019.104668","article-title":"In silico drug repurposing for the identification of potential candidate molecules against arboviruses infection","volume":"173","author":"D Montes-Grajales","year":"2020","journal-title":"Antiviral Res"},{"issue":"49","key":"pntd.0010291.ref053","doi-asserted-by":"crossref","first-page":"31365","DOI":"10.1073\/pnas.2005463117","article-title":"Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors","volume":"117","author":"RPM Abrams","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7881","key":"pntd.0010291.ref054","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/s41586-021-03990-6","article-title":"A pan-serotype dengue virus inhibitor targeting the NS3-NS4B interaction","volume":"598","author":"SJF Kaptein","year":"2021","journal-title":"Nature"},{"issue":"579","key":"pntd.0010291.ref055","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abb2181","article-title":"NITD-688, a pan-serotype inhibitor of the dengue virus NS4B protein, shows favorable pharmacokinetics and efficacy in preclinical animal models.","volume":"13","author":"SA Moquin","year":"2021","journal-title":"Sci Transl Med"},{"key":"pntd.0010291.ref056","doi-asserted-by":"crossref","first-page":"2040206618761299","DOI":"10.1177\/2040206618761299","article-title":"Nucleoside analogs as a rich source of antiviral agents active against arthropod-borne flaviviruses.","volume":"26","author":"L Eyer","year":"2018","journal-title":"Antivir Chem Chemother"},{"issue":"10","key":"pntd.0010291.ref057","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1038\/ctg.2017.51","article-title":"Seven-Year Treatment Outcome of Entecavir in a Real-World Cohort: Effects on Clinical Parameters, HBsAg and HBcrAg Levels.","volume":"8","author":"YF Lam","year":"2017","journal-title":"Clin Transl Gastroenterol."},{"issue":"3","key":"pntd.0010291.ref058","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1177\/1756283X13515825","article-title":"Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential.","volume":"7","author":"C Stedman","year":"2014","journal-title":"Therap Adv Gastroenterol"},{"key":"pntd.0010291.ref059","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3389\/fmicb.2020.00139","article-title":"Current Antivirals and Novel Botanical Molecules Interfering With Herpes Simplex Virus Infection.","volume":"11","author":"DM Alvarez","year":"2020","journal-title":"Front Microbiol."},{"key":"pntd.0010291.ref060","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.antiviral.2015.11.009","article-title":"Tenofovir alafenamide: A novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus","volume":"125","author":"AS Ray","year":"2016","journal-title":"Antiviral Res"},{"issue":"7496","key":"pntd.0010291.ref061","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature13027","article-title":"Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430","volume":"508","author":"TK Warren","year":"2014","journal-title":"Nature"},{"issue":"3","key":"pntd.0010291.ref062","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jiph.2016.04.002","article-title":"BCX4430\u2014A broad-spectrum antiviral adenosine nucleoside analog under development for the treatment of Ebola virus disease","volume":"9","author":"R Taylor","year":"2016","journal-title":"J Infect Public Health"},{"key":"pntd.0010291.ref063","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.antiviral.2017.03.012","article-title":"Antiviral activity of the adenosine analogue BCX4430 against West Nile virus and tick-borne flaviviruses","volume":"142","author":"L Eyer","year":"2017","journal-title":"Antiviral Res"},{"key":"pntd.0010291.ref064","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.antiviral.2016.11.003","article-title":"Efficacy of the broad-spectrum antiviral compound BCX4430 against Zika virus in cell culture and in a mouse model","volume":"137","author":"JG Julander","year":"2017","journal-title":"Antiviral Res"},{"issue":"48","key":"pntd.0010291.ref065","doi-asserted-by":"crossref","first-page":"20435","DOI":"10.1073\/pnas.0907010106","article-title":"An adenosine nucleoside inhibitor of dengue virus","volume":"106","author":"Z Yin","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"pntd.0010291.ref066","doi-asserted-by":"crossref","first-page":"ofw175","DOI":"10.1093\/ofid\/ofw175","article-title":"Adenosine Analog NITD008 Is a Potent Inhibitor of Zika Virus.","volume":"3","author":"YQ Deng","year":"2016","journal-title":"Open Forum Infect Dis."},{"key":"pntd.0010291.ref067","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.antiviral.2015.12.008","article-title":"Optimizing celgosivir therapy in mouse models of dengue virus infection of serotypes 1 and 2: The search for a window for potential therapeutic efficacy","volume":"127","author":"S Watanabe","year":"2016","journal-title":"Antiviral Res"},{"issue":"5","key":"pntd.0010291.ref068","doi-asserted-by":"crossref","first-page":"e0004695","DOI":"10.1371\/journal.pntd.0004695","article-title":"The Viral Polymerase Inhibitor 7-Deaza-2\u2019-C-Methyladenosine Is a Potent Inhibitor of In Vitro Zika Virus Replication and Delays Disease Progression in a Robust Mouse Infection Model.","volume":"10","author":"J Zmurko","year":"2016","journal-title":"PLoS Negl Trop Dis."},{"issue":"3","key":"pntd.0010291.ref069","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02093-18","article-title":"Viral RNA-Dependent RNA Polymerase Inhibitor 7-Deaza-2\u2019-C-Methyladenosine Prevents Death in a Mouse Model of West Nile Virus Infection","volume":"63","author":"L Eyer","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"pntd.0010291.ref070","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00654-20","article-title":"A Cyclic Phosphoramidate Prodrug of 2\u2019-Deoxy-2\u2019-Fluoro-2\u2019-C-Methylguanosine for the Treatment of Dengue Virus Infection.","volume":"64","author":"R Karuna","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"pntd.0010291.ref071","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1002\/eji.200939389","article-title":"Depletion of macrophages in mice results in higher dengue virus titers and highlights the role of macrophages for virus control","volume":"39","author":"K Fink","year":"2009","journal-title":"Eur J Immunol"},{"issue":"11","key":"pntd.0010291.ref072","doi-asserted-by":"crossref","first-page":"e0098821","DOI":"10.1128\/AAC.00988-21","article-title":"Evaluation of AT-752, a Double Prodrug of a Guanosine Nucleotide Analog with In Vitro and In Vivo Activity against Dengue and Other Flaviviruses","volume":"65","author":"SS Good","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"pntd.0010291.ref073","article-title":"Safety, pharmacokinetics and antiviral activity of AT-527, a novel purine nucleotide prodrug, in HCV-infected subjects with and without cirrhosis","author":"E Berliba","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"pntd.0010291.ref074","article-title":"AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 In Vitro and a Promising Oral Antiviral for Treatment of COVID-19","volume":"65","author":"SS Good","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"pntd.0010291.ref075","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.antiviral.2017.12.016","article-title":"Discovery of a non-nucleoside RNA polymerase inhibitor for blocking Zika virus replication through in silico screening","volume":"151","author":"A Pattnaik","year":"2018","journal-title":"Antiviral Res"},{"key":"pntd.0010291.ref076","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.antiviral.2016.11.023","article-title":"The FDA-approved drug sofosbuvir inhibits Zika virus infection","volume":"137","author":"KM Bullard-Feibelman","year":"2017","journal-title":"Antiviral Res"},{"issue":"1","key":"pntd.0010291.ref077","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/s41598-018-19526-4","article-title":"Blocking Zika virus vertical transmission.","volume":"8","author":"P Mesci","year":"2018","journal-title":"Sci Rep."},{"issue":"4","key":"pntd.0010291.ref078","doi-asserted-by":"crossref","first-page":"e1001628","DOI":"10.1371\/journal.pmed.1001628","article-title":"Fialuridine induces acute liver failure in chimeric TK-NOG mice: a model for detecting hepatic drug toxicity prior to human testing","volume":"11","author":"D Xu","year":"2014","journal-title":"PLoS Med"},{"issue":"4","key":"pntd.0010291.ref079","doi-asserted-by":"crossref","first-page":"278","DOI":"10.4103\/0976-500X.142464","article-title":"Sofosbuvir: A novel treatment option for chronic hepatitis C infection.","volume":"5","author":"HK Bhatia","year":"2014","journal-title":"J Pharmacol Pharmacother"},{"issue":"3","key":"pntd.0010291.ref080","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1093\/infdis\/jiu377","article-title":"Repurposing of prochlorperazine for use against dengue virus infection","volume":"211","author":"Y Simanjuntak","year":"2015","journal-title":"J Infect Dis"},{"issue":"4","key":"pntd.0010291.ref081","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1172\/JCI89857","article-title":"Anticancer kinase inhibitors impair intracellular viral trafficking and exert broad-spectrum antiviral effects","volume":"127","author":"E Bekerman","year":"2017","journal-title":"J Clin Invest"},{"key":"pntd.0010291.ref082","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.antiviral.2018.05.001","article-title":"Feasibility and biological rationale of repurposing sunitinib and erlotinib for dengue treatment","volume":"155","author":"SY Pu","year":"2018","journal-title":"Antiviral Res"},{"issue":"3","key":"pntd.0010291.ref083","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.immuni.2017.02.012","article-title":"25-Hydroxycholesterol Protects Host against Zika Virus Infection and Its Associated Microcephaly in a Mouse Model","volume":"46","author":"C Li","year":"2017","journal-title":"Immunity"},{"issue":"12","key":"pntd.0010291.ref084","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1099\/jgv.0.000309","article-title":"Chloroquine inhibited Ebola virus replication in vitro but failed to protect against infection and disease in the in vivo guinea pig model","volume":"96","author":"SD Dowall","year":"2015","journal-title":"J Gen Virol"},{"issue":"3","key":"pntd.0010291.ref085","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.","volume":"30","author":"M Wang","year":"2020","journal-title":"Cell Res"},{"issue":"3","key":"pntd.0010291.ref086","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1089\/vim.2014.0090","article-title":"Antiviral activity of chloroquine against dengue virus type 2 replication in Aotus monkeys","volume":"28","author":"KJ Farias","year":"2015","journal-title":"Viral Immunol"},{"issue":"12","key":"pntd.0010291.ref087","doi-asserted-by":"crossref","DOI":"10.3390\/v8120322","article-title":"Chloroquine, an Endocytosis Blocking Agent, Inhibits Zika Virus Infection in Different Cell Models.","volume":"8","author":"R Delvecchio","year":"2016","journal-title":"Viruses"},{"key":"pntd.0010291.ref088","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ebiom.2017.09.034","article-title":"Chloroquine, a FDA-approved Drug, Prevents Zika Virus Infection and its Associated Congenital Microcephaly in Mice.","volume":"24","author":"C Li","year":"2017","journal-title":"EBioMedicine."},{"issue":"8","key":"pntd.0010291.ref089","doi-asserted-by":"crossref","first-page":"e785","DOI":"10.1371\/journal.pntd.0000785","article-title":"A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults.","volume":"4","author":"V Tricou","year":"2010","journal-title":"PLoS Negl Trop Dis"},{"issue":"5","key":"pntd.0010291.ref090","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1590\/S0074-02762013000500010","article-title":"Chloroquine use improves dengue-related symptoms","volume":"108","author":"MC Borges","year":"2013","journal-title":"Mem Inst Oswaldo Cruz"},{"issue":"1","key":"pntd.0010291.ref091","doi-asserted-by":"crossref","first-page":"17565","DOI":"10.1038\/s41598-017-17770-8","article-title":"The celecoxib derivatives AR-12 and AR-14 induce autophagy and clear prion-infected cells from prions.","volume":"7","author":"BA Abdulrahman","year":"2017","journal-title":"Sci Rep."},{"key":"pntd.0010291.ref092","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.antiviral.2017.02.015","article-title":"AR-12 suppresses dengue virus replication by down-regulation of PI3K\/AKT and GRP78","volume":"142","author":"HH Chen","year":"2017","journal-title":"Antiviral Res"},{"issue":"1","key":"pntd.0010291.ref093","first-page":"187","article-title":"Novel AR-12 derivatives, P12-23 and P12-34, inhibit flavivirus replication by blocking host de novo pyrimidine biosynthesis","volume":"7","author":"CF Yang","year":"2018","journal-title":"Emerg Microbes Infect"},{"key":"pntd.0010291.ref094","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.virol.2019.10.010","article-title":"Zika virus NS5 nuclear accumulation is protective of protein degradation and is required for viral RNA replication","volume":"541","author":"W Ji","year":"2020","journal-title":"Virology"},{"issue":"5","key":"pntd.0010291.ref095","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/ja.2017.11","article-title":"Ivermectin: enigmatic multifaceted \u2019wonder\u2019 drug continues to surprise and exceed expectations.","volume":"70","author":"A. Crump","year":"2017","journal-title":"J Antibiot (Tokyo)."},{"key":"pntd.0010291.ref096","doi-asserted-by":"crossref","first-page":"104760","DOI":"10.1016\/j.antiviral.2020.104760","article-title":"The broad spectrum antiviral ivermectin targets the host nuclear transport importin alpha\/beta1 heterodimer","volume":"177","author":"SNY Yang","year":"2020","journal-title":"Antiviral Res"},{"issue":"1","key":"pntd.0010291.ref097","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.diagmicrobio.2019.03.012","article-title":"Lack of efficacy of ivermectin for prevention of a lethal Zika virus infection in a murine system","volume":"95","author":"H Ketkar","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"key":"pntd.0010291.ref098","unstructured":"Yamasmith E. Efficacy and safety of ivermectin against dengue infection: a phase III, randomized, double-blind, placebo-controlled trial. The 34th Annual Meeting the Royal College of Physicians of Thailand Internal Medicine and One Health; Chonburi, Thailand. 2018."},{"key":"pntd.0010291.ref099","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/978-981-10-8727-1_20","article-title":"Mechanisms of Antiviral Activity of Iminosugars Against Dengue Virus","volume":"1062","author":"JL Miller","year":"2018","journal-title":"Adv Exp Med Biol"},{"key":"pntd.0010291.ref100","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.antiviral.2016.03.001","article-title":"Inhibition of endoplasmic reticulum glucosidases is required for in vitro and in vivo dengue antiviral activity by the iminosugar UV-4","volume":"129","author":"KL Warfield","year":"2016","journal-title":"Antiviral Res"},{"issue":"5","key":"pntd.0010291.ref101","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.3390\/v7052404","article-title":"A Novel Iminosugar UV-12 with Activity against the Diverse Viruses Influenza and Dengue (Novel Iminosugar Antiviral for Influenza and Dengue).","volume":"7","author":"KL Warfield","year":"2015","journal-title":"Viruses"},{"issue":"1","key":"pntd.0010291.ref102","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1080\/22221751.2019.1604084","article-title":"Targeting host metabolism by inhibition of acetyl-Coenzyme A carboxylase reduces flavivirus infection in mouse models","volume":"8","author":"N Jimenez de Oya","year":"2019","journal-title":"Emerg Microbes Infect"},{"issue":"2","key":"pntd.0010291.ref103","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00350-17","article-title":"N-Methyl-d-Aspartate (NMDA) Receptor Blockade Prevents Neuronal Death Induced by Zika Virus Infection.","volume":"8","author":"VV Costa","year":"2017","journal-title":"mBio"},{"issue":"1","key":"pntd.0010291.ref104","doi-asserted-by":"crossref","DOI":"10.1242\/bio.031807","article-title":"Niclosamide rescues microcephaly in a humanized in vivo model of Zika infection using human induced neural stem cells","volume":"7","author":"DM Cairns","year":"2018","journal-title":"Biol Open"},{"issue":"8","key":"pntd.0010291.ref105","doi-asserted-by":"crossref","first-page":"e0006715","DOI":"10.1371\/journal.pntd.0006715","article-title":"The antiparasitic drug niclosamide inhibits dengue virus infection by interfering with endosomal acidification independent of mTOR.","volume":"12","author":"JC Kao","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"key":"pntd.0010291.ref106","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2017.08.007","article-title":"Ribavirin inhibits Zika virus (ZIKV) replication in vitro and suppresses viremia in ZIKV-infected STAT1-deficient mice.","volume":"146","author":"N Kamiyama","year":"2017","journal-title":"Antiviral Res"},{"issue":"1","key":"pntd.0010291.ref107","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.antiviral.2010.11.002","article-title":"Combination of alpha-glucosidase inhibitor and ribavirin for the treatment of dengue virus infection in vitro and in vivo","volume":"89","author":"J Chang","year":"2011","journal-title":"Antiviral Res"},{"key":"pntd.0010291.ref108","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.antiviral.2017.06.006","article-title":"Emetine inhibits replication of RNA and DNA viruses without generating drug-resistant virus variants","volume":"144","author":"N Khandelwal","year":"2017","journal-title":"Antiviral Res"},{"key":"pntd.0010291.ref109","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41421-018-0034-1","article-title":"Emetine inhibits Zika and Ebola virus infections through two molecular mechanisms: inhibiting viral replication and decreasing viral entry","volume":"4","author":"S Yang","year":"2018","journal-title":"Cell Discov"},{"key":"pntd.0010291.ref110","doi-asserted-by":"crossref","first-page":"14972","DOI":"10.1038\/srep14972","article-title":"Design, Synthesis and Structure-Activity Relationship Optimization of Lycorine Derivatives for HCV Inhibition.","volume":"5","author":"D Chen","year":"2015","journal-title":"Sci Rep."},{"issue":"2","key":"pntd.0010291.ref111","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1128\/AAC.02274-15","article-title":"A Conserved Inhibitory Mechanism of a Lycorine Derivative against Enterovirus and Hepatitis C Virus","volume":"60","author":"Y Guo","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"pntd.0010291.ref112","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.virol.2020.04.009","article-title":"Antiviral activity of lycorine against Zika virus in vivo and in vitro","volume":"546","author":"H Chen","year":"2020","journal-title":"Virology"},{"issue":"21","key":"pntd.0010291.ref113","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01055-17","article-title":"Screening of FDA-Approved Drugs for Inhibitors of Japanese Encephalitis Virus Infection","volume":"91","author":"S Wang","year":"2017","journal-title":"J Virol"},{"issue":"12","key":"pntd.0010291.ref114","doi-asserted-by":"crossref","first-page":"18132","DOI":"10.1021\/acsomega.8b01002","article-title":"Hydroxychloroquine Inhibits Zika Virus NS2B-NS3 Protease.","volume":"3","author":"A Kumar","year":"2018","journal-title":"ACS Omega."},{"issue":"8","key":"pntd.0010291.ref115","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1084\/jem.20170957","article-title":"Inhibition of autophagy limits vertical transmission of Zika virus in pregnant mice","volume":"214","author":"B Cao","year":"2017","journal-title":"J Exp Med"},{"key":"pntd.0010291.ref116","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.antiviral.2015.10.005","article-title":"Inhibition of dengue virus production and cytokine\/chemokine expression by ribavirin and compound A","volume":"124","author":"T Rattanaburee","year":"2015","journal-title":"Antiviral Res"},{"issue":"2","key":"pntd.0010291.ref117","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.stem.2017.06.017","article-title":"High-Content Screening in hPSC-Neural Progenitors Identifies Drug Candidates that Inhibit Zika Virus Infection in Fetal-like Organoids and Adult Brain","volume":"21","author":"T Zhou","year":"2017","journal-title":"Cell Stem Cell"},{"key":"pntd.0010291.ref118","article-title":"Clinical Pharmacology Perspectives on the Antiviral Activity of Azithromycin and Use in COVID-19","author":"B Damle","year":"2020","journal-title":"Clin Pharmacol Ther"},{"issue":"50","key":"pntd.0010291.ref119","doi-asserted-by":"crossref","first-page":"14408","DOI":"10.1073\/pnas.1618029113","article-title":"Zika virus cell tropism in the developing human brain and inhibition by azithromycin","volume":"113","author":"H Retallack","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"pntd.0010291.ref120","doi-asserted-by":"crossref","first-page":"e0006848","DOI":"10.1371\/journal.pntd.0006848","article-title":"ICR suckling mouse model of Zika virus infection for disease modeling and drug validation.","volume":"12","author":"YH Wu","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"issue":"8","key":"pntd.0010291.ref121","doi-asserted-by":"crossref","first-page":"e3025","DOI":"10.1371\/journal.pntd.0003025","article-title":"Dengue therapeutics, chemoprophylaxis, and allied tools: state of the art and future directions.","volume":"8","author":"J Whitehorn","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"issue":"8","key":"pntd.0010291.ref122","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1021\/acs.jcim.1c00404","article-title":"Strengths and Weaknesses of Docking Simulations in the SARS-CoV-2 Era: the Main Protease (Mpro) Case Study.","volume":"61","author":"MA Llanos","year":"2021","journal-title":"J Chem Inf Model."},{"issue":"8","key":"pntd.0010291.ref123","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23081899","article-title":"Binding Affinity via Docking: Fact and Fiction.","volume":"23","author":"T Pantsar","year":"2018","journal-title":"Molecules"},{"issue":"8","key":"pntd.0010291.ref124","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1016\/S0968-0896(02)00051-2","article-title":"X-ray crystallographic structure of ABT-378 (lopinavir) bound to HIV-1 protease.","volume":"10","author":"V Stoll","year":"2002","journal-title":"Bioorg Med Chem"},{"issue":"15","key":"pntd.0010291.ref125","doi-asserted-by":"crossref","first-page":"5083","DOI":"10.1093\/nar\/gkn464","article-title":"Crystal engineering of HIV-1 reverse transcriptase for structure-based drug design","volume":"36","author":"JD Bauman","year":"2008","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"pntd.0010291.ref126","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.tibs.2021.06.008","article-title":"Drug discovery in the era of cryo-electron microscopy","volume":"47","author":"MJ Robertson","year":"2022","journal-title":"Trends Biochem Sci"},{"issue":"22","key":"pntd.0010291.ref127","doi-asserted-by":"crossref","first-page":"127524","DOI":"10.1016\/j.bmcl.2020.127524","article-title":"Cryo-EM as a powerful tool for drug discovery","volume":"30","author":"JH Van Drie","year":"2020","journal-title":"Bioorg Med Chem Lett"},{"issue":"1","key":"pntd.0010291.ref128","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41467-020-20542-0","article-title":"Mechanism of SARS-CoV-2 polymerase stalling by remdesivir.","volume":"12","author":"G Kokic","year":"2021","journal-title":"Nat Commun."},{"issue":"6554","key":"pntd.0010291.ref129","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1126\/science.abi4708","article-title":"Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2","volume":"373","author":"TA Tummino","year":"2021","journal-title":"Science"},{"issue":"6","key":"pntd.0010291.ref130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/rmv.2121","article-title":"The association between dengue viremia kinetics and dengue severity: A systemic review and meta-analysis.","volume":"30","author":"S Morsy","year":"2020","journal-title":"Rev Med Virol"},{"issue":"9","key":"pntd.0010291.ref131","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1093\/infdis\/jir014","article-title":"Kinetics of plasma viremia and soluble nonstructural protein 1 concentrations in dengue: differential effects according to serotype and immune status","volume":"203","author":"HT Duyen","year":"2011","journal-title":"J Infect Dis"},{"key":"pntd.0010291.ref132","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1186\/s13071-014-0590-7","article-title":"Evaluation of host and viral factors associated with severe dengue based on the 2009 WHO classification.","volume":"7","author":"JO Pozo-Aguilar","year":"2014","journal-title":"Parasit Vectors."},{"issue":"10","key":"pntd.0010291.ref133","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1016\/j.drudis.2021.05.008","article-title":"Drug combination therapy for emerging viral diseases.","volume":"26","author":"ZA Shyr","year":"2021","journal-title":"Drug Discov Today"},{"issue":"3","key":"pntd.0010291.ref134","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.jacbts.2019.02.005","article-title":"Phase II Trials in Drug Development and Adaptive Trial Design.","volume":"4","author":"GA Van Norman","year":"2019","journal-title":"JACC Basic Transl Sci"},{"issue":"8","key":"pntd.0010291.ref135","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/S1473-3099(14)70730-3","article-title":"Efficacy and safety of celgosivir in patients with dengue fever (CELADEN): a phase 1b, randomised, double-blind, placebo-controlled, proof-of-concept trial.","volume":"14","author":"JG Low","year":"2014","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"pntd.0010291.ref136","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1093\/infdis\/jis470","article-title":"A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients","volume":"207","author":"NM Nguyen","year":"2013","journal-title":"J Infect Dis"},{"issue":"9","key":"pntd.0010291.ref137","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1093\/cid\/cis655","article-title":"Effects of short-course oral corticosteroid therapy in early dengue infection in Vietnamese patients: a randomized, placebo-controlled trial","volume":"55","author":"DT Tam","year":"2012","journal-title":"Clin Infect Dis"},{"issue":"4","key":"pntd.0010291.ref138","first-page":"468","article-title":"Lovastatin for the Treatment of Adult Patients With Dengue: A Randomized, Double-Blind, Placebo-Controlled Trial","volume":"62","author":"J Whitehorn","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"3","key":"pntd.0010291.ref139","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1128\/JVI.02841-13","article-title":"Activation of peripheral blood mononuclear cells by dengue virus infection depotentiates balapiravir","volume":"88","author":"YL Chen","year":"2014","journal-title":"J Virol"},{"issue":"10236","key":"pntd.0010291.ref140","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Y Wang","year":"2020","journal-title":"Lancet"},{"issue":"10","key":"pntd.0010291.ref141","doi-asserted-by":"crossref","first-page":"e0111721","DOI":"10.1128\/AAC.01117-21","article-title":"Why Remdesivir Failed: Preclinical Assumptions Overestimate the Clinical Efficacy of Remdesivir for COVID-19 and Ebola","volume":"65","author":"VC Yan","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"pntd.0010291.ref142","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.dmpk.2020.04.333","article-title":"Species differences in liver accumulation and metabolism of nucleotide prodrug sofosbuvir","volume":"35","author":"T Wang","year":"2020","journal-title":"Drug Metab Pharmacokinet"},{"issue":"19","key":"pntd.0010291.ref143","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the Treatment of Covid-19\u2014Final Report","volume":"383","author":"JH Beigel","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"pntd.0010291.ref144","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/20477724.2021.1890887","article-title":"Phase 2 randomized study on chloroquine, hydroxychloroquine or ivermectin in hospitalized patients with severe manifestations of SARS-CoV-2 infection.","volume":"115","author":"LEB Galan","year":"2021","journal-title":"Pathog Glob Health"},{"key":"pntd.0010291.ref145","doi-asserted-by":"crossref","first-page":"100720","DOI":"10.1016\/j.eclinm.2020.100720","article-title":"The effect of early treatment with ivermectin on viral load, symptoms and humoral response in patients with non-severe COVID-19: A pilot, double-blind, placebo-controlled, randomized clinical trial.","volume":"32","author":"C Chaccour","year":"2021","journal-title":"EClinicalMedicine."},{"issue":"4","key":"pntd.0010291.ref146","doi-asserted-by":"crossref","first-page":"e208857","DOI":"10.1001\/jamanetworkopen.2020.8857","article-title":"Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial.","volume":"3","author":"MGS Borba","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"12","key":"pntd.0010291.ref147","article-title":"A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19","volume":"64","author":"Y Doi","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"19","key":"pntd.0010291.ref148","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1056\/NEJMoa2001282","article-title":"A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19","volume":"382","author":"B Cao","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"pntd.0010291.ref149","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in Hospitalized Patients with Covid-19","volume":"384","author":"RC Group","year":"2021","journal-title":"N Engl J Med"},{"issue":"13","key":"pntd.0010291.ref150","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1001\/jama.2020.17021","article-title":"Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19: The CoDEX Randomized Clinical Trial","volume":"324","author":"BM Tomazini","year":"2020","journal-title":"JAMA"},{"key":"pntd.0010291.ref151","volume-title":"HIV Antiretroviral Therapy.","author":"TR Kemnic","year":"2021"},{"issue":"4","key":"pntd.0010291.ref152","first-page":"a007161","article-title":"HIV-1 antiretroviral drug therapy.","volume":"2","author":"EJ Arts","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"pntd.0010291.ref153","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3389\/fpubh.2017.00032","article-title":"HIV Diagnosis and Treatment through Advanced Technologies.","volume":"5","author":"HF Zulfiqar","year":"2017","journal-title":"Front Public Health."},{"key":"pntd.0010291.ref154","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.antiviral.2017.02.014","article-title":"Current therapy for chronic hepatitis C: The role of direct-acting antivirals","volume":"142","author":"G Li","year":"2017","journal-title":"Antiviral Res"},{"issue":"4","key":"pntd.0010291.ref155","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jhep.2016.06.019","article-title":"Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis","volume":"65","author":"MCM Cheung","year":"2016","journal-title":"J Hepatol"}],"container-title":["PLOS Neglected Tropical Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0010291","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T17:28:09Z","timestamp":1651166889000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pntd.0010291"}},"subtitle":[],"editor":[{"given":"Louis","family":"Lambrechts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,4,28]]},"references-count":155,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,4,28]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pntd.0010291","relation":{},"ISSN":["1935-2735"],"issn-type":[{"value":"1935-2735","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,28]]}}}